HENDERSON, Nev., Oct. 3, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:
VNRX) ("Volition"), a multi-national epigenetics company, is
hosting a symposium at ESICM Lives 2024 in Barcelona on October 7,
2024, during which experts from across the globe will
present findings from large, independent studies regarding the
potential of using Nu.Q® NETs to determine a 'treatable trait'
to enhance sepsis management.
The session, entitled 'NETs: Casting a new light on sepsis
management', will take place at 12.30 pm CET
on Monday, October 7, and will be chaired by Professor
Djillali Annane, a world-renowned
expert in sepsis.
Professor Djillali Annane,
Professor of Medicine at University Paris Saclay-UVSQ, said:
"Volition's ESICM symposium will bring together distinguished
experts in the field of sepsis to share research findings around
the potential use of Volition's Nu.Q® NETs H3.1 assay in clinical
practice.
"It is becoming increasingly evident that Nu.Q® NETs could play
an integral role in the management of sepsis. Elevated levels of
H3.1 are both a marker of badness and a cause of consequence.
During the session, we will explore the role of H3.1 nucleosomes in
NETosis; the clinical utility of H3.1 in a range of recent,
large-scale studies, and examine how the Nu.Q® NETs biomarker
has the potential to predict organ failure.
"As a Critical Care Consultant, I see the devastating effects of
this disease each day. I believe Nu.Q® NETs, as a diagnostic tool,
has the potential to bring about a paradigm shift in sepsis
management. I hope that Nu.Q® NETs becomes widely available - in
every intensive care unit, in every hospital setting - to help
ensure we detect, treat, and monitor sepsis earlier and save
lives."
Nu.Q® NETs, Volition's nucleosome quantification technology, is
a simple, low-cost, accessible test that quantifies an individual's
level of circulating H3.1 nucleosomes in the bloodstream, a
surrogate marker for Neutrophil Extracellular Traps (NETs).
Although NETs play a critical role in our normal immune response,
elevated levels of NETs can lead to tissue damage, and in severe
cases, sepsis, organ failure and death.
ESICM Lives 2024 is the annual congress of the European Society
of Intensive Care Medicine and brings together intensive care
physicians, anesthetists, nursing, and allied health professionals
from over 100 countries worldwide.
Note:
Sepsis is the number one cause of death in hospitals worldwide
and accounts for at least 11 million deaths per year (Global Sepsis
Alliance 2024).
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life. For more
information about Volition's technology go to:
www.volition.com.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the potential uses, benefits and
effectiveness of Volition's Nu.Q® technology platform. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic, prognostic or disease monitoring
products, it may be unable to execute its plan of operations. Other
risks and uncertainties include Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; a failure by the marketplace to accept the
products in Volition's development pipeline or any other
diagnostic, prognostic or disease monitoring products Volition
might develop; Volition's failure to secure adequate intellectual
property protection; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring market
and its rapid technological change; downturns in domestic and
foreign economies; and other risks, including those identified in
Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. These statements
are based on current expectations, estimates and projections about
Volition's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this press release, and, except as required by law,
Volition does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Media Enquiries:
Louise Batchelor/Debra
Daglish
Volition
mediarelations@volition.com
+44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volition-hosts-nets-in-sepsis-management-symposium-at-esicm-lives-2024-302266731.html
SOURCE VolitionRx Limited